Cargando…

In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia

Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Spottiswoode, Natasha, Hao, Samantha, Sanchez-Guerrero, Estella, Detweiler, Angela M., Mekonen, Honey, Neff, Norma, Macmillan, Henriette, Schwartz, Brian S., Engel, Joanne, DeRisi, Joseph L., Miller, Steven A., Langelier, Charles R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499174/
https://www.ncbi.nlm.nih.gov/pubmed/37712060
http://dx.doi.org/10.3389/fcimb.2023.1241608
_version_ 1785105650375720960
author Spottiswoode, Natasha
Hao, Samantha
Sanchez-Guerrero, Estella
Detweiler, Angela M.
Mekonen, Honey
Neff, Norma
Macmillan, Henriette
Schwartz, Brian S.
Engel, Joanne
DeRisi, Joseph L.
Miller, Steven A.
Langelier, Charles R.
author_facet Spottiswoode, Natasha
Hao, Samantha
Sanchez-Guerrero, Estella
Detweiler, Angela M.
Mekonen, Honey
Neff, Norma
Macmillan, Henriette
Schwartz, Brian S.
Engel, Joanne
DeRisi, Joseph L.
Miller, Steven A.
Langelier, Charles R.
author_sort Spottiswoode, Natasha
collection PubMed
description Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The infections demonstrated unusual, progressive increases in resistance to beta lactam antibiotics in the setting of active treatment with appropriate, guideline-directed agents. WGS followed by comparative genomic analysis of isolates collected over 44 days demonstrated in host evolution of a single P. aeruginosa isolate characterized by stepwise acquisition of two de-novo genetic resistance mechanisms over the course of treatment. We found a novel deletion affecting the ampC repressor ampD and neighboring gene ampE, which associated with initial cefepime treatment failure. This was followed by acquisition of a porin nonsense mutation, OprD, associated with resistance to carbapenems. This study highlights the potential for in-host evolution of P. aeruginosa during bloodstream infections in severely immunocompromised patients despite appropriate antimicrobial therapy. In addition, it demonstrates the utility of WGS for understanding unusual resistance patterns in the clinical context.
format Online
Article
Text
id pubmed-10499174
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104991742023-09-14 In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia Spottiswoode, Natasha Hao, Samantha Sanchez-Guerrero, Estella Detweiler, Angela M. Mekonen, Honey Neff, Norma Macmillan, Henriette Schwartz, Brian S. Engel, Joanne DeRisi, Joseph L. Miller, Steven A. Langelier, Charles R. Front Cell Infect Microbiol Cellular and Infection Microbiology Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The infections demonstrated unusual, progressive increases in resistance to beta lactam antibiotics in the setting of active treatment with appropriate, guideline-directed agents. WGS followed by comparative genomic analysis of isolates collected over 44 days demonstrated in host evolution of a single P. aeruginosa isolate characterized by stepwise acquisition of two de-novo genetic resistance mechanisms over the course of treatment. We found a novel deletion affecting the ampC repressor ampD and neighboring gene ampE, which associated with initial cefepime treatment failure. This was followed by acquisition of a porin nonsense mutation, OprD, associated with resistance to carbapenems. This study highlights the potential for in-host evolution of P. aeruginosa during bloodstream infections in severely immunocompromised patients despite appropriate antimicrobial therapy. In addition, it demonstrates the utility of WGS for understanding unusual resistance patterns in the clinical context. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10499174/ /pubmed/37712060 http://dx.doi.org/10.3389/fcimb.2023.1241608 Text en Copyright © 2023 Spottiswoode, Hao, Sanchez-Guerrero, Detweiler, Mekonen, Neff, Macmillan, Schwartz, Engel, DeRisi, Miller and Langelier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Spottiswoode, Natasha
Hao, Samantha
Sanchez-Guerrero, Estella
Detweiler, Angela M.
Mekonen, Honey
Neff, Norma
Macmillan, Henriette
Schwartz, Brian S.
Engel, Joanne
DeRisi, Joseph L.
Miller, Steven A.
Langelier, Charles R.
In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title_full In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title_fullStr In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title_full_unstemmed In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title_short In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
title_sort in host evolution of beta lactam resistance during active treatment for pseudomonas aeruginosa bacteremia
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499174/
https://www.ncbi.nlm.nih.gov/pubmed/37712060
http://dx.doi.org/10.3389/fcimb.2023.1241608
work_keys_str_mv AT spottiswoodenatasha inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT haosamantha inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT sanchezguerreroestella inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT detweilerangelam inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT mekonenhoney inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT neffnorma inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT macmillanhenriette inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT schwartzbrians inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT engeljoanne inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT derisijosephl inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT millerstevena inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia
AT langeliercharlesr inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia